Ksana Health and Children's Wisconsin Announce Innovative Digital Mental Health Partnership to Enhance Pediatric Behavioral Health Care
Currently, approximately 20% of children ages 3-17 experience mental and behavioral health disorders, yet up to 80% of these youth do not receive the necessary care. With 90% of children seen annually in pediatric primary care (PPC) settings, these facilities are ideally positioned for early identification and treatment of youth mental health challenges. The integration of mental health services directly into pediatric primary care has been recognized as essential to addressing this critical gap, which is why Children's Wisconsin has made integrating mental health into primary care a system-wide priority.
Leveraging the Pediatric Primary Care Integrated Behavioral Health model, this partnership introduces the cutting-edge digital behavioral health care platform, Vira by Ksana Health, to enhance existing behavioral health services. Vira employs artificial intelligence to reinforce evidence-based therapeutic principles, smart automations to optimize clinical workflows to reduce the burden on health care providers, and personalized mobile interventions designed to support the health of youth and their families.
"We see enormous potential in digital mental health tools to empower clinicians and families with continuous, data-driven behavioral support," said Dr. Michael Gaffrey, Craig Yabuki Research Chair and Director of Mental and Behavioral Health Research at Children's Wisconsin. "This collaboration marks a significant step forward in realizing a sustainable, effective integration of mental health services within pediatric primary care."
This initiative underscores the commitment of Ksana Health and Children's Wisconsin to improving pediatric behavioral health care accessibility, adherence to evidence-based practice and the long-term sustainability of integrated mental health care.
"Our goal is to revolutionize pediatric behavioral health by making effective, personalized interventions accessible precisely when youth and families need them," added Dr. Nick Allen, CEO of Ksana Health. "Together, we're committed to addressing the mental health crisis facing today's youth with practical, scalable solutions that work."
About Ksana Health: Ksana Health develops advanced digital behavioral health care platforms integrating AI and evidence-based methodologies to support clinicians, improve service delivery, and empower patients in managing their mental well-being.
About Children's WisconsinChildren's Wisconsin is the region's only independent health care system dedicated solely to the health and well-being of children. The hospital, with locations in Milwaukee and Neenah, Wisconsin, is recognized as one of the leading pediatric health care centers in the United States. It is ranked among the top pediatric hospitals in the country by U.S. News & World Report's 2023-24 Best Children's Hospitals report. Children's Wisconsin provides primary care, specialty care, urgent care, emergency care, mental and behavioral health care, community health services, foster and adoption services, child and family counseling, child advocacy services and family resource centers. In 2022, Children's invested more than $171 million in the community to improve the health status of children through medical care, advocacy, education and pediatric medical research. Children's achieves its mission in part through donations from individuals, corporations and foundations and is proud to be a member of Children's Miracle Network Hospitals.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ksana-health-and-childrens-wisconsin-announce-innovative-digital-mental-health-partnership-to-enhance-pediatric-behavioral-health-care-302474528.html
SOURCE Ksana Health
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Organ Preservation Market worth $0.3 billion by 2030 with 6.8% CAGR
DELRAY BEACH, Fla., July 21, 2025 /PRNewswire/ --The global Organ Preservation Market, valued at US$0.1 billion in 2024 stood at US$0.2 billion in 2025 and is projected to advance at a resilient CAGR of 6.8% from 2025 to 2030, culminating in a forecasted valuation of US$0.3 billion by the end of the period. The organ preservation market is experiencing robust growth fueled by rising incidence of chronic diseases, organ failure, and advancements in transplantation procedures. Increasing rates of end-stage organ conditions—such as kidney, liver, and heart failure—combined with a growing global demand for transplant procedures are key factors accelerating market expansion. The aging population, more susceptible to organ dysfunction, further highlights the increasing need for effective preservation methods to maintain organ viability pre-transplantation. Technological progress in preservation techniques, including hypothermic and normothermic perfusion, is transforming the standard of care by enhancing organ function and extending preservation times. In parallel, developing innovative preservation solutions such as the University of Wisconsin (UW) solution and Custodiol HTK significantly improves transplantation outcomes. Rising awareness among healthcare providers and the public about timely organ donation and preservation is increasing product adoption. Expanding hospital transplant programs, supportive government initiatives, and improved healthcare infrastructure in emerging markets also drive market momentum. Download PDF Brochure: Browse in-depth TOC on "Organ Preservation Market" 300 - Tables 100 - Figures 400 - Pages By solution, the organ preservation market, by solution, is categorized into UW Solution, Custodial HTK, Perfadex, and other solutions (including EuroCollins and Celsior). The UW (University of Wisconsin) solution accounted for the largest market share in 2024. This solution is widely used for preserving and flushing organs such as the liver, kidneys, and pancreas. As the first intracellular solution introduced for this purpose, it has become the benchmark in organ preservation. The dominance of the UW solution can be credited to its high efficacy in improving transplant outcomes. This is primarily due to the inclusion of metabolically inactive compounds like lactobionate and raffinose, which help reduce tissue damage, maintain cellular integrity, and enhance the physiological viability of organs during storage. These advantages have made the UW solution preferred over alternative preservation media. By technique, the static cold storage segment is expected to dominate the market due to its simplicity, cost-effectiveness, and widespread use in preserving kidneys, liver, and pancreas. While newer technologies such as hypothermic machines and normothermic perfusion are gaining traction, especially for heart and lung preservation, static cold storage remains the gold standard in many transplant centers worldwide. In addition, ongoing advancements in perfusion technologies and a growing focus on organ quality optimization before transplantation are expanding the market. The increasing initiatives by governments and non-profits to promote organ donation, along with improvements in preservation solutions and transportation logistics, are further contributing to market growth. As the demand for transplantable organs continues to outpace supply, efficient and advanced preservation methods become more crucial in ensuring transplant success. By organ type, Organ preservation, categorized by organ type, includes kidneys, liver, lungs, heart, and pancreas. In 2024, the kidney segment emerged as the leading contributor to the market. This prominence is primarily due to the rising prevalence of end-stage renal disease (ESRD), for which kidney transplantation remains the most effective treatment option. As kidney failure cases continue to grow, so does the number of transplant procedures, necessitating efficient preservation of donor kidneys before implantation in recipients. By end user, the organ preservation market is divided into transplant centers, hospitals, and specialty clinics. In 2024, the organ transplant centers segment accounted for the largest share of the market. The large share of this segment can be attributed to the extensive establishment of healthcare facilities that operate dedicated transplant programs. These centers are central to organ retrieval, preservation, and transplantation, making them critical consumers of preservation products and technologies. By geography, The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific region is attributed to supportive government policies, rising public awareness regarding organ donation, and a surge in organ donation activities. Countries like China and Japan have implemented standardized national guidelines for organ donation and transplantation, which are playing a key role in advancing the market. Additionally, improvements in healthcare infrastructure, the increasing burden of chronic illnesses, and the rise of medical tourism across several countries in the region are expected to fuel the market growth during the forecast period. Request Sample Pages : The prominent players in the global organ preservation market are Paragonix Technologies (US), XVIVO Perfusion AB (Sweden), Dr. Franz Köhler Chemie GmbH (Germany), Essential Pharmaceuticals, LLC (US), TransMedics (US), OrganOx Limited (UK), 21st Century Medicine (US), Shanghai Genext Medical Technology (China), Bridge to Life Limited (US), Waters Medical Systems (US), Preservation Solutions (US), Carnamedica (Poland), Transplant Biomedicals (Spain), Institut Georges Lopez (France), Global Transplant Solutions (US), Avionord (Italy), Organ Preservation Solutions (England), EBERS (Spain), S.A.L.F. (Italy), Biochefa (Poland), Vascular Perfusion Solutions, Inc. (US), and TX Innovations (Netherlands). Paragonix (US): Paragonix is the leading market player in organ preservation. It operates mainly in the US and Europe. The company has been focused on developments such as new product launches, partnerships, agreements, and approvals since 2016. The company has developed devices for all thoracic & abdominal organ preservation. Paragonix also focuses on software services and tools for real-time organ tracking. Paragonix partnered with the Lung Transplant Foundation (US) to develop various technologies to improve donor lung preservation. In January 2021, the company partnered with Southwest Transplant Alliance (STA) to provide advanced organ preservation technologies. Such a development proves the company's strong market prevalence. XVIVO Perfusion AB (Sweden) XVIVO Perfusion AB is a prominent market and public domain company. It is headquartered in Sweden and operates in Europe, Asia, the Middle East, and North & South America. It spends nearly 31% of its revenue on R&D, which is why the company is involved in developing improved products for organ perfusion. XVIVO's lung perfusion solution is used mainly in Lung Preservation, making the solution a gold standard. In September 2020, XVIVO Perfusion entered an acquisition agreement with Organ Assist. This agreement further strengthened the company's product range and expanded its addressable market. Dr. Franz Kohler Chemie GmbH (Germany) Dr. Franz Kohler Chemie GmbH is a leading market player in organ preservation solutions since 1959. It involves developing electrolyte solutions, organ-protective solutions, therapeutics, antidotes, X-ray contrast agents, and medical devices. It has captured the market for Custodial, an organ preservation solution. Custodial holds advantages over other solutions, like reduced viscosity and an improved graft survival rate, and is widely used to preserve all organs, unlike other solutions. These advantages of a Custodial solution for organ preservation prove that Dr. Franz Kohler Chemie GMBH holds a substantial market prevalence. For more information, Inquire Now! Related Reports: Biopreservation Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Electrophysiology Market Human Organoids Market Transplant Diagnostics Market Get access to the latest updates on Organ Preservation Companies and Organ Preservation Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Kalorama Information's 2025 IVD Atlas Tracks Global Growth Hotspots, Led by China and Emerging Markets
ARLINGTON, Va., July 14, 2025 /PRNewswire/ -- Kalorama Information, a leading authority in healthcare market intelligence, announces the release of its 30-Country IVD Market Atlas, 2025 (June Update)—an in-depth strategic resource offering the most comprehensive, country-specific analysis of the in vitro diagnostics (IVD) landscape across 30 key nations. With quarterly updates throughout the year, this data-rich report equips stakeholders with timely and actionable insights to navigate the fast-evolving global diagnostics market. Timely Updates. Local Precision. Global Impact. From the U.S., China, and Germany to Vietnam, Saudi Arabia, and South Africa, Kalorama's 30-Country IVD Market Atlas delivers granular market sizing, forecasts through 2029, and segmentation across 20+ critical IVD categories, including: Molecular diagnostics (HIV, Hepatitis, Respiratory, HAI) POC testing (Pregnancy, Glucose, Infectious Disease) Immunoassays, Coagulation, Hematology, Histology Microbiology and Core Lab/Critical Care Unlike fragmented or outdated country reports, this atlas provides a single, continuously updated source for understanding demand, regulation, and competition across the globe — ideal for strategic planning, product launches, market expansion, and M&A targeting. Highlights in the 2025 June Update China emerges as the fastest-growing IVD market of the 30 countries tracked, with a projected CAGR nearing 9% through 2029—almost four times the growth of slower-expanding markets like Egypt, Russia, and Japan."China is one of the world's largest and fastest-growing IVD markets, making it a key target for major vendors seeking to offset slower growth in developed economies," said Daniel Granderson, Senior Editor at Kalorama Information. "In 2024, glucose monitoring alone accounted for over 20% of China's IVD value—and that momentum is just beginning." Countries such as Saudi Arabia, South Korea, Turkey, Vietnam, and the UAE are all forecast to exceed 5% CAGR, driven by expanding healthcare access, chronic disease burden, and tech adoption. Russia's IVD market negatively impacted due to the withdrawal of foreign businesses surrounding the Ukraine war. The rise of AI, home testing, and personalized medicine continues to reshape diagnostics delivery across nearly all regions. Who Should Read This Report? The 30-Country IVD Market Atlas is designed for: Executive leadership and strategic planners at diagnostic and medtech companies Product and portfolio managers making localization or phase-out decisions Business development teams scouting M&A and partnership opportunities Investors and private equity analysts assessing country-level growth targets Regulatory professionals tracking compliance landscapes and approval trends Get the Report Today To access the full report or schedule a custom consultation, visit:Purchase the 30-Country IVD Market Atlas, 2025 For custom research or enterprise access, contact:Sheri Davie – Sales Director, Kalorama For media inquiries, contact:Richa Singh – Vice President, Strategic & Insights About Kalorama Information A division of Science and Medicine Group, Kalorama Information has been a trusted publisher of healthcare market research for over 25 years. Its analysts specialize in in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, and other authoritative benchmarks in the global medical technology space. Kalorama works in close coordination with SMG brands including BioInformatics, SDi, and IMV, enabling deep insight across diagnostics, life sciences, and imaging markets. Learn more at View original content to download multimedia: SOURCE Kalorama Information Sign in to access your portfolio
Associated Press
9 hours ago
- Associated Press
Shoulder Innovations Announces Closing of a $40 Million Convertible Notes Financing
GRAND RAPIDS, Mich., July 21, 2025 /PRNewswire/ -- Shoulder Innovations, a medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the closing of a $40 million convertible notes financing by new investor Fidelity Management & Research Company. Proceeds from the financing will be used primarily to support continued commercialization of Shoulder Innovations' advanced implant systems for anatomic total shoulder arthroplasty (aTSA) and reverse total shoulder arthroplasty (rTSA), as well as for new product development. Shoulder Innovations' InSet™ Glenoid technology serves as the foundation for the company's aTSA and rTSA implant systems and includes a novel biomechanical design that aims to reduce stress at the bone implant interface, improve fixation mechanics, enhance stability, and reduce micromotion to specifically address glenoid loosening, a primary problem in shoulder arthroplasty. Both implant systems leverage consistent surgical techniques and the same efficient, two tray instrumentation system. 'Shoulder Innovations is transforming shoulder surgical care with a purpose-built ecosystem, designed to deliver predictable outcomes and procedural efficiency across all sites of care,' said Rob Ball, CEO of Shoulder Innovations. 'We appreciate the support with this investment and believe these proceeds will help us to advance our mission to redefine shoulder arthroplasty and enable best-in-class outcomes for shoulder specialists and their patients.' About Shoulder Innovations: Shoulder Innovations is a medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care. View original content to download multimedia: SOURCE Shoulder Innovations
